FROM OUR EXPERTS
Last week, the Food and Drug Administration (FDA) listened to presentations and comments from several members of an expert FDA advisory committee regarding the benefit-to-risk ratio of Long Acting Beta-agonist drugs (LABAs) -- namely Serevent (salmeterol) , Foradil (formoterol) , Advair (a combination of fluticasone and salmeterol) and Symbicort (a combination of budesonide and formoterol).
The FDA advisory panel voted, unanimously, that the benefit of Advair and Symbicort outweighed the risks of adverse effects in adults , but that the risks of Serevent and Foradil -- particularly when used without a anti-inflammatory steroid -- outweighed the benefits for asthmatics.
So, what does all of this mean for you?
Continue reading "Advair and Symbicort: "Benefits Outweight the Risk" Says an FDA Advisory Comittee.
Get more information on Advair, Symbicort and Long-Acting Beta Agonists here.
So what's the deal with Advair and Symbicort? These meds have helped so many asthmatics finally gain control of their asthma, yet, with all the recent warnings, the FDA seems to be wary of these meds, and this is scaring people.
Should we be wary and quit taking them? Or, should we continue to use these meds to control asthma? I personally agree with Dr. Matthew Minz that you should fear not. Allow me to explain.
Both Advair and Symbicort contain a Long Acting Beta Adrenergic (LABA) to keep the air passages in your lungs from spasming. In Advair the LABA is Serevent, in Symbicort the LABA is Formoterol.
Some reports say LABAs are linked to worsening asthma and even death, such as this warning about Advair: "University of Iowa researchers have added their voices to growing warnings about Advair, saying that drugs that use salmeterol in combination with an inhaled corticosteroid can make asthma more severe or even f...
While the economy sputters, the long acting bronchodilator/ corticosteroid combination inhaler market is booming. While big pharmaceutical companies fight it out to maintain or gain a piece of this pie, we asthmatics should be the beneficiaries.
New drugs, and new marketing ploys, may soon be available in the U.S. market to compete with Advair and Symbicort, which will provide more options for asthmatics like you and me. Plus, as we all know, more competition means lower costs.
Advair and Symbicort are asthma combination inhalers that have both a long acting bronchodilator (LAB) to treat the airway narrowing (bronchospasm) component of asthma, but also a corticosteroid to treat the chronic inflammation side of asthma.
Advair (called Seritide in Europe), which is marketed by GlaxoSmithKline (GSK) out of London, became available in the U.S. in 2001, and presently has the lead in this booming market. Adviar consists of the LAB Salmeterol (Serev...
You should know
Answers to your question are meant to provide general health information but should not replace medical advice you receive from a doctor. No answers should be viewed as a diagnosis or recommended treatment for a condition. Content posted by community members does not necessarily reflect the views of Remedy Health Media, which also reserves the right to remove material deemed inappropriate.